Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Resources>Webcasts>This Webcast
Strategic Applications of Flow Chemistry within Drug Discovery
Paul Richardson, Synthesis Group Leader, Pfizer, speaking at Flow Chemistry Congress.
Date Posted: Tuesday, October 16, 2012

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

No Business Split for Pfizer
Pfizer decides remaining one company best positions company to maximize future value creation.
Tuesday, September 27, 2016
Pfizer to Acquire AstraZeneca Antibiotics
Pfizer has announced that it has entered an agreement with AstraZeneca to acquire its late-stage small molecule business for up to $1.575 billion.
Wednesday, August 24, 2016
Pfizer's $14Bn Acquisition of Medivation
It has been announced that Pfizer will acquire Medivation for $81.50 a share for a total value of roughly $14 billion.
Tuesday, August 23, 2016
Pfizer Acquires Bamboo Therapeurtics for $645M
Pfizer aims to become industry leader in gene therapy with aquisition of Bamboo Therapeutics.
Monday, August 01, 2016
Pfizer, Western Oncolytics Research Collaboration
Pfizer and Western Oncolytics have announced an immuno-oncology research collaboration.
Friday, July 29, 2016
Pfizer's $40M Bid for BIND Therapeutics
BIND Therapeutics announced Pfizer's $40 million winning bid at a Section 363 asset auction.
Thursday, July 28, 2016
Pfizer Advances Biosimilars Leadership with Investment in Biotechnology Center
Company has announced that the facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms.
Tuesday, June 28, 2016
Pfizer Breaks Ground On New Biologics Facility
The company has broken ground for its new biologics clinical manufacturing facility in Andover, Massachusetts.
Monday, June 20, 2016
Pfizer to Acquire Anacor
Company has entered into a merger agreement under which it will acquire Anacor for $99.25 per Anacor share in cash.
Thursday, May 19, 2016
Pfizer, IBM Collaboration Aims to Transform Parkinson’s Disease Care
Experimental “Internet of Things” system uses connected devices to enable remote measurement of health and quality of life in real-time.
Thursday, April 07, 2016
Pfizer Terminates $160bn Allergan Deal
Proposed merger agreement between Pfizer and Allergan has been terminated by mutual agreement of the companies.
Wednesday, April 06, 2016
Pfizer, Calibr Collaborate
The California Institute for Biomedical Research (Calibr), a nonprofit translational research institute, has announced that it has entered into a global strategic collaboration with Pfizer Inc. to develop novel antibody-based therapeutic agents for the treatment of heart failure.
Friday, January 15, 2016
Pfizer, Adaptive Biotechnologies Collaborate
Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise.
Monday, January 11, 2016
Pfizer and Allergan to Combine
This move will create a new global biopharmaceutical leader with best-in-class innovative and established businesses
Tuesday, November 24, 2015
Pfizer and Synthon Enter into U.S. Commercialization Agreement
Synthon’s glatiramer acetate, a potential generic version of Copaxone®1 for the treatment of relapsing remitting multiple sclerosis is currently being reviewed by the U.S. Food and Drug Administration.
Friday, August 07, 2015
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos